HERMS ANALYTICS

Turn complex evidence into clear decisions.

Connect scientific, clinical, regulatory, manufacturing, safety and commercial evidence to compare options, identify gaps and prioritise action.

Bring a decision into focus. Understand the evidence behind each answer, the uncertainty around it and the next step requiring qualified review.

Decision workspaceILLUSTRATIVE ANALYTICS VIEW

Evidence readiness

Source recordsAvailable
ComparabilityIncomplete
Transfer planRequires review

Scenario comparison

Relative resource needs · hypothetical inputs; no recommendation implied.

Connected consequences

Manufacturing change
Quality · Regulatory · Supply
Evidence & decision gates

Next review priorities

Resolve comparability gap
Owner: CMC reviewer
Challenge transfer assumptions
Gate: readiness review

Demonstration content only. Statuses and relative bars are hypothetical and do not represent a client, validated model output or measured performance.

ANALYSIS THAT SUPPORTS ACTION

Ask the question. Examine the evidence. Decide the next step.

HERMS analytics is designed to make options, dependencies and evidence gaps explicit across specialist workflows. The examples below illustrate the analytical approach.

Evidence readiness

Is the evidence sufficient to progress?

Assess completeness, relevance, consistency and uncertainty. Identify missing evidence and questions requiring qualified review.

Scientific rationaleAvailable
Supporting evidenceIncomplete
Progression decisionRequires review
Illustrative evidence matrix

Comparative analysis

Which option best fits the objective?

Compare development pathways, genome-editing strategies, technology-transfer options, manufacturing configurations and market-access scenarios against explicit criteria.

ILLUSTRATIVE OPTION COMPARISON
CriterionOption AOption B
EvidenceGap identifiedReview needed
DependenciesSite readinessMethod transfer
Next stepClose gapTest assumption

Scenario analysis

What changes when assumptions change?

Explore how alternative costs, timelines, process yields, evidence requirements and access conditions affect programme choices.

Base caseCurrent assumptions and evidence requirements
AlternativeChanged timeline, process yield or facility choice
SensitivityIdentify assumptions that materially change the conclusion
Scenario framework · outputs depend on supplied data and methods

Dependencies & consequences

What else does this decision affect?

Trace how a scientific finding, process change or emerging safety concern affects connected requirements, risks, milestones and investment decisions.

New evidence or process change
Requirements · risks · timelines · investment
Review affected decisions
Illustrative dependency map

Risk & priorities

What needs attention next?

Prioritise material risks, unresolved evidence gaps and approaching decision gates according to their potential impact and urgency.

ILLUSTRATIVE ACTION PANEL
PriorityOwnerNext review
Evidence gapDomain reviewerBefore progression
Process assumptionTechnical leadReadiness gate

Traceable outputs

Understand the basis of every conclusion.

Present supporting sources, analytical methods, assumptions, uncertainty and reviewer decisions alongside the result.

SourceDocument, version, date and relevant passage
MethodAnalytical approach and transformation steps
UncertaintyAssumptions, limitations and missing evidence
ReviewResponsible reviewer and recorded decision
Illustrative evidence trail

SIX ANALYTICAL DOMAINS

Connect specialist insight across the programme.

Explore related questions across scientific translation, technology transfer, manufacturing, regulatory access, safety, governance and investment.

Scientific & Clinical

Discovery, genome editing, advanced therapies, clinical design and value evidence.

Technology Transfer & Manufacturing

IP, know-how, receiving-site readiness, scale-up, validation and manufacturing networks.

Regulatory & Market Access

Pathways, submission gaps, pricing, HTA, tenders and access agreements.

Safety & Supply

Safety signals, distribution, shipping validation, cold-chain integrity and resilience.

Integrity & Governance

Research integrity, engagement ethics, privacy, evidence integrity and model assurance.

Capital & Portfolio

Opportunity prioritisation, milestone funding, investment scenarios and portfolio trade-offs.

ILLUSTRATIVE CONNECTED ANALYSIS

Which manufacturing transfer option is ready for review?

Connect IP and know-how, process design, receiving-site capability, quality requirements, regulatory dependencies and investment assumptions in one structured comparison.

DEFINE

Set the decision criteria

Specify the objective, product and process scope, receiving-site options, evidence requirements and responsible reviewers.

ANALYSE

Compare the evidence

Examine rights and know-how, scale-up and validation needs, regulatory consequences, timelines and economic assumptions.

REVIEW

Agree the next evidence gate

Present gaps, sensitivities and dependencies so qualified people can decide what must be resolved before progression.

An analytical comparison supports expert review. It does not itself establish regulatory acceptability, clinical benefit, manufacturing readiness or investment approval.

Bring a decision.
Explore the evidence.

Define your analytical question and the evidence needed for a focused demonstration.

Illustrative analytics views use demonstration content. Available methods, data inputs and validation requirements are confirmed for each engagement.

ENGINEERING INTELLIGENCE. REVOLUTIONIZING LIFE SCIENCES.

HERMS is the intelligence platform. Its applications are the decision engines. HERMS expert services support implementation and regulated execution of the HERMS intelligence ecosystem, from regulatory and market access to pharmacovigilance, compliance and quality.

Drug registration timelines by country · SFDA, MOHAP, EDE, EDA, EMA and FDA timelines · GCC central registration